...
Panel | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||
Anchor |
|
Anchor | ||||
---|---|---|---|---|
|
- If a patient is >= 5 years old, completes a COVID-19 vaccine series via the Pfizer COVID-19 (5-17) 2-dose series and receives an additional shot of CVX 218, CVX 208, CVX 217, CVX 207, or CVX 213:
- at < 28 days after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 28 days required for an Additional Dose for immunocompromised patients or the minimum interval of 5 months required for a Booster Dose." at >= 28 days and
- Once a patient completes:
- a the Moderna COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, recommend Series,
- and is < 5 years old, the recommendation is Not Recommended and the reason code is COMPLETE.
- and is < 18 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
and is >= 18 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months) or at recommended age (
1218 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE
.and receives an additional
dose1dose1 (see “Rules for Additional Dose” for information on what constitutes an additional dose and how is evaluated), the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
See “Rules for Booster Dose” for booster dose recommendations for the these seriesModerna COVID-19 Series.
- the Moderna Pfizer COVID-19 Series or Mixed Product Series,
- and is < 5 years old, the recommendation is Not Recommended and the reason code is COMPLETE.and is < 18 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- and is >= 18 5 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months) or at recommended age (18 5 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE.
and receives an additional dose1 (see “Rules for Additional Dose” for information on what constitutes an additional dose and how is evaluated), the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
See “Rules for Booster Dose” for booster dose recommendations for the Moderna Pfizer COVID-19
(5-17) 2-doseSeries.
- the Pfizer Janssen COVID-19 Series or Mixed Product Series
and is < 5 years old, the recommendation is Not Recommended and the reason code is COMPLETE.1-dose series,- and is >= 5 12 years old, recommend recommend a booster dose of COVID-19 (at vaccine group level) at at recommended interval (5 months) or at recommended age (5 years), whichever date is later8 weeks), along with recommendation reason code BOOSTER_DOSE.
- and receives an additional dose1, the Recommendation is Conditional is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- and receives a booster dose2, the Recommendation is Not Recommended and the reason code is COMPLETE.
See “Rules for Booster Dose” for booster dose recommendations for the Janssen COVID-19 1-dose series
- and is >= 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), along with recommendation reason code BOOSTER_DOSE.
- and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
See “Rules for Booster Dose” for booster dose recommendations for the Janssen COVID-19 1-dose series.
- a the Moderna COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, recommend Series,
Rules for an Additional Dose1
- If a patient completes a COVID-19 vaccine series via the Pfizer COVID-19 series, Moderna COVID-19 series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives an additional shot of CVX 207, CVX 208, CVX 213, CVX 217, CVX 218, CVX 219, CVX 227 or CVX 228:
- at < 5 months after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 5 months required for the 1st Booster Dose."
- at >= 5 months after series completion, then evaluate the shot as Valid.
.
a COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine,
recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months) or at recommended age (12 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE.
and receives an additional dose1 (see “Rules for Additional Dose” for information on what constitutes an additional dose and how is evaluated), the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
See “Rules for Booster Dose” for booster dose recommendations for the these series.
Rules for an Additional Dose1
- If a patient completes a COVID-19 vaccine series via the Pfizer COVID-19 series, Moderna COVID-19 series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives an additional shot of CVX 207, CVX 208, CVX 213, CVX 217, CVX 218, CVX 219, CVX 227 or CVX 228:
- at < 5 months after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text:
- "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 5 months required for
a - the 1st Booster Dose."
- at >= 5 months after series completion, then evaluate the shot as Valid.
If a patient completes a COVID-19 vaccine series via the Janssen 1-dose series and receives an additional shot of CVX 207, CVX 208, CVX 213, CVX 217, CVX 218, CVX 219, CVX 227 or CVX 228:
at < 8 weeks after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 8 weeks required for the 1st Booster Dose"
at >= 8 weeks after series completion, then evaluate the shot as Valid.
Rules for Booster Dose2
Any of the FDA-Approved COVID-19 vaccines (except CVX 218) can be used for booster vaccination, regardless of the vaccine product used for primary vaccination. When a heterologous or “mix and match” booster dose is administered, the eligible population and dosing intervals are those of the vaccine used for primary vaccination.
Recommendation Rules for Booster Dose
First Booster Dose
After completion of a COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine
Recommended Age = 12.
Recommendation Rules for Booster Dose
- Recommend at the Vaccine Group Level (along with recommendation reason code BOOSTER_DOSE)
First Booster Dose
After completion of the Moderna COVID-19 Series
Recommended Age = 18 years
Minimum Age = 12 18 years
Recommended Interval = 5 months
Include recommendation reason Code ADMINISTER_mRNA_VACCINE (new reason code)
After completion of the Moderna Pfizer COVID-19 Series or Mixed Product Series
Recommended Age = 18 5 years
Minimum Age = 18 5 years
Recommended Interval = 5 months
After completion of the Pfizer COVID-19 Series or Mixed Product SeriesJanssen 1-dose series
Recommended Age = 5 12 years
Minimum Age = 5 12 years
Recommended Interval = 5 months8 weeks
After completion of Janssen 1-dose seriesa COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine
Recommended Age = 12 years
Minimum Age = 12 years
Recommended Interval = 8 weeks
5 months
Include recommendation reason Code ADMINISTER_mRNA_VACCINE (new reason code)
Second Booster Dose:
After completion of the first booster in the Pfizer Series, Moderna
Series, Mixed Product Series, a COVID-19 vaccine series not authorized by the FDA but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine:If the patient is < 50 years of age, recommend Conditional / COMPLETE_HIGH_RISK.
Otherwise:
Minimum Age = 50 years
Recommended Age = 50 years
Recommended Interval = 4 months
After completion of first booster dose in the Janssen series:
If the patient >= 12 years of age and < 18 years of age:
Recommend Conditional / COMPLETE_HIGH_RISK
If the patient >= 18 years of age:
and <50 years:
Recommend Conditional / COMPLETE_HIGH_RISK if first booster dose was an mRNA vaccine (CVX 207, CVX 208, CVX 213, CVX 217 or CVX 221)
and >=50 years:
Recommended Age = 50 years if first booster dose was an mRNA vaccine (CVX 207, CVX 208, CVX 213, CVX 217, or CVX 221)
Recommended Age = 18 years if first booster dose was the Janssen vaccine (CVX 212)
Recommended Interval = 4 months
After completion of the 2nd second booster dose2 (must be mRNA), the Recommendation is Not Recommended and the reason code is COMPLETE.
Evaluation Rules for Booster Dose
- Any of the FDA-Approved COVID-19 vaccines (except CVX 218) are allowed for both Booster Doses.
- Absolute Minimum Interval = 0 days
- First Booster Dose:
- If a patient completes a COVID-19 vaccine series via the Pfizer COVID-19 series, Moderna 2COVID-dose 19 series, Mixed Product COVID-19 Series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives a Booster Dose2 of CVX 207, CVX 208, CVX 212, CVX 213, CVX 217 or CVX 221:
- at < 5 months after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 5 months required for a Booster Dose."
- at >= 5 months after series completion, then evaluate the shot as Valid.
- If a patient completes a COVID-19 vaccine series via the Janssen 1-dose series and receives a Booster Dose2 of CVX 207, CVX 208, CVX 212, CVX 213, CVX 217 or CVX 221:
- at < 8 weeks after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 8 weeks required for a Booster Dose."
- at >= 8 weeks after series completion, then evaluate the shot as Valid.
- If a patient completes a COVID-19 vaccine series via the Pfizer COVID-19 series, Moderna 2COVID-dose 19 series, Mixed Product COVID-19 Series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives a Booster Dose2 of CVX 207, CVX 208, CVX 212, CVX 213, CVX 217 or CVX 221:
- Second Booster Dose:
If a patient completes a COVID-19 vaccine series via the Pfizer COVID-19 Series, Moderna COVID-19 Series, Mixed Product COVID-19 Series, Janssen 1-dose series, COVID COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives a Booster Dose2 of CVX 208, CVX 217, CVX 207, CVX 212, CVX 213 or CVX 221:
at < 4 months after the first booster dose, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text: “"The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 4 months required for the 2nd Booster Dose."
at >= 4 months after the first booster dose, evaluate the shot as Valid.
Rules for Evaluation of Extra Shots
After AdditionalAfter Additional Dose1and/
or Boosteror Booster Doses
2In2
For patients that completed the Pfizer COVID-19 Series and Mixed Product COVID-19 Series:
is < 5 years old, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is > = 5 years old and < 50 years old and received an Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 50 years of age and Additional Dose and/or Booster Dose, and 2nd Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
and Additional Dose and/or 1st Booster Dose and 2nd Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
For patients that completed the Moderna COVID-19 2-dose series:
is < 5 years old, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE
is >= 5 years old and < 18 years old and received an Additional Dose, any shots administered afterwards at < 18 years of age will be evaluated as Accepted/EXTRA_DOSE
is >= 18 years old and < 50 years old and received an Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 50 years of age and Additional Dose and/or Booster Dose, and 2nd Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
and Additional Dose and/or 1st Booster Dose and 2nd Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
For patients that completed Janssen COVID-19 1-dose series:
is < 5 years old, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 5 years old and < 50 years old and received an Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 50 years of age and Additional Dose and/or Booster Dose, and 2nd Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
and Additional Dose and/or 1st Booster Dose and 2nd Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
For patients that completed either the 1) COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a 2) COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, Additional Dose and/or first Booster Dose, and 2nd booster dose, any shots administered after the primary series is evaluated as Accepted/EXTRA_DOSE.
...
CVX Code | Name | Absolute Minimum Age | Absolute Maximum Age | Counts towards U.S. Vaccination |
---|---|---|---|---|
207 | Moderna COVID-19 Vaccine | 0 days | Yes | |
208 | Pfizer COVID-19 Vaccine | 0 days | Yes | |
210 | AstraZeneca COVID-19 Vaccine | 0 days | Yes, only if all recommended doses are administered. | |
211 | Novavax COVID-19 Vaccine | 0 days | Yes, only if all recommended doses are administered. | |
212 | Janssen COVID-19 Vaccine | 0 days | Yes | |
213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | 0 days | Yes | |
217 | Pfizer COVID-19 Vaccine (>= 12 years) | 0 days | Yes | |
218 | Pfizer COVID-19 Vaccine (5-11 years)Vaccine | 0 days | 18 years - 1 day | Yes |
219 | Pfizer COVID-19 Vaccine (Preferable age range: >= 6 months to < 5 years)Pfizer COVID-19 Vaccine | 0 days | 6 years - 1 day | Yes |
221 | Moderna COVID-19 Vaccine (Preferable age ranges: >= 6 years to < 12 years OR >= 18 years)Vaccine | 0 days | Yes | |
227 | Moderna COVID-19 Vaccine (Inactive) | 0 days | 13 years - 1 day | Yes |
228 | Moderna COVID-19 Vaccine (Preferable age range: >= 6 months to < 6 years) | 0 days | 7 years - 1 day | Yes |
500 | COVID-19 Non-US Vaccine, Product Unknown | No | ||
501 | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) | No | ||
502 | COVID-19 IV Non-US Vaccine (COVAXIN) | 0 days | Yes, only if all recommended doses are administered. | |
503 | COVID-19 LAV Non-US Vaccine (COVIVAC) | No | ||
504 | COVID-19 VVnr Non-US Vaccine (Sputnik Light) | No | ||
505 | COVID-19 VVnr Non-US Vaccine (Sputnik V) | No | ||
506 | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology) | No | ||
507 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbology Chinese academy of Sciences) | No | ||
508 | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) | No | ||
509 | COVID-19 PS Non-US Vaccine (EpiVacCorona) | No | ||
510 | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | 0 days | Yes, only if all recommended doses are administered. | |
511 | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | 0 days | Yes, only if all recommended doses are administered. | |
512 | COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) | 18 years - 4 days | Yes, only if all recommended doses are administered. | |
513 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) | No | ||
514 | COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) | No | ||
515 | COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) | No | ||
516 | COVID-19 Inactivated Non-US Vaccine (Minhai Biotechnology Co, KCONVAC) | No | ||
517 | COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) | No |
...
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
CVX Code Specific RulesCVX Code Absolute Minimum Age
CVX Code Absolute Maximum Age
Absolute Minimum Interval Rule for Moderna Vaccines (Remove this rule)
Rule for CVX 213
Rules for COVID-19 Vaccines Not Authorized by FDA2The following set of rules apply to 1) COVID-19 Vaccines Not Authorized by FDA, but Authorized by WHO and, 2) COVID-19 Vaccines Not Authorized by FDA or WHO, but is an Active COVID-19 Vaccine Candidate as part of a U.S.-based Clinical Trial of a COVID-19 Vaccine.
|
...
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Name
Series Selection RulesThere are four series for this vaccine group: the Pfizer COVID-19 series, Moderna COVID-19 series, Mixed Product COVID-19 series, and the Janssen COVID-19 1-dose series. The rules for determining which series applies are:
|
Immunization Series: Pfizer COVID-19 Series
The Pfizer COVID-19 Child (6 months - 17 years) Series is complete after 2 or 3 doses, depending on age (not including booster dose(s)).
...
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Skip Dose Rule
Rule for CVX 218
Rule for CVX 212 (Janssen COVID-19 Vaccine)
|
...
Immunization Series: Moderna COVID-19 Series
The Pfizer COVID-19 Child (5-17) 2-dose Series is complete after 2 doses. The Moderna COVID-19 series is complete after 2 doses(not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
...
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) | |
---|---|---|---|---|---|---|
Dose 1 to 2 | Moderna COVID-19 | 0 days if dose 2 administer < 10/25/2021 24 days if dose 2 administered >= 10/25/2021 | 24 days | 28 days | 28 days | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Vaccine to Recommend
Rule for CVX 212 (Janssen COVID-19 Vaccine)
|
Immunization Series: Mixed Product COVID-19 Series Series
The Pfizer Mixed Product COVID-19 2-dose series is complete after 2 or 3 doses. , depending on age(not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
...
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Vaccine to RecommendRecommend at the vaccine group level.Skip Dose Rule
Rule for CVX 218
Rule for CVX 212 (Janssen COVID-19 Vaccine)
|
Immunization Series: Janssen COVID-19 1-dose Series
...